CHRNA4 and cancer: αB-CTX is a novel and important nicotinic acetylcholine receptor (nAChR) antagonist, with the greatest potency against the α9α10 subtype [7], and it is worth noting that the α9α10 nAChR is an important target for the development of analgesics and cancer chemotherapeutics [8,9,10,11].